Hi Guys back of Holiday but not yet really settled down. Needed the break as I havent had a holiday in 5 years. Just been resting up at home.

Back to the stocks. Well lets face it last week was a stinker, simple as that. Interest rates hike hanging over the market and the tiddlers getting hurt most as all of the extra cost will fall to the bottom line. Lets hope for a better week.

Update on stocks.

I D DATA- hoping for this one to carry on from Friday and start to rise again. About 4 weeks to results so we may get a good run plus a contract win is get to be confirmed.

INCITE HOLDINGS - strange happenings at this company last week but apparantley big orders were being filled for institutional players, in fact a pal of mine on another site who is a big holder was contacted to see if he wanted to sell any of his holding and he gave them a quick no chance answer.

BEMA GOLD - fell back by about 10 points last week on averageish results. Fact of the matter is that a Miner should be judged on NAV and not earnings, due to physical nature of the business.

JUST CAR CLINICS - TA uptrend in place and company released two very interesting pieces of news on its web site that should see further support.

CENTURION ELECTRONICS - gave back a bit of ground last week but uptrend trully in place.

HCEG - another that gave ground back last week but there was some good news later in the week refering to warrants. Seems holders on a certain date will be awarded a warrant for every XXX share held . Ask me in the morning.

PIPEX - changed name last week had an up and down week but I added yet again. Great growth potential here.

NEW RECOMMENDATION

Going to go in for SCI ENTERTAINMENT SEG in the morning. Saturday paper confirmed that trading was well in front of budget and this backed up what Evil Knievil had been saying last week. EK feels that this is one of the cheapest stocks on the Whole Market, and we should get a good run up to Xmas with the new Desert Storm offering (sorry not an expert on games).
DYOR and if you buy watch the spread in the first hour or so, the MMS read the newspapers just like us, dont get sucked in. Remember you are responsible for your own buy and sell actions, we dont want any whimps complaining if they lose money. Only use money that you camn afford to lose and remember this is investing. If you want a quick fix, I suggest you go down to your local bookies , casino or boozer and play on the one armed bandit. We are all adults.

gf.

ps, sorry forgot Service Power Tech - special update on that sometime monday.

Ciao, SRG was subject to profit taking but dont worry the long term curve is upwards.

Good luck freind.

cheers GF.

Watch out for Centurion Electronics making a break out.

GF.

What a bummer of a day. Think Ill do my last gardening for the year until spring next year. See you tonight.

cheers GF.

GF CUC was on my "action list"...got in this morning at 124.38... I am now in the money...

When time checkout TOA....

Ciao

Will do ciao. Its a reyt bummer of a day mate. Will go in yond back garden and pulls some weeds up cock.

cheers GF.

Well didnt miss too much this afternoon, maybe we will have a good one in the morning.

Star of the day being BEMA Gold up over 12% in after hours in the US, should take it over the 200p mark.

Centurion Electronics was up again and ScI Entertainment turned around in the afternoon and gained 1p.

cheers Gf.

Hi GF see what you think of RPP, I took profit the other day... yesterday did well again ....I belive could be a good one to put away long....


PRELIMINARY RESULTS FOR THE PERIOD ENDED 30 SEPTEMBER 2003

RingProp plc, the marine propeller design and sales company, today announces its
results for the 14 month period ended 30 September 2003.

RingProp plc was formed to exploit the potential of a ground-breaking marine
propeller technology, the 'RingProp'. The company which has its head office at
the Haslar Marine Technology Park, was floated on the AIM market on 22 November
2002 and a total of 3,264,065, before flotation expenses, was raised.

Progress to date

Since flotation the group has been researching in detail the market and
technology of the RingProp concept. In July 2003, the group agreed a major
strategic manufacturing venture in collaboration with a leading international
diecasting company, JL French (UK) Ltd. This work, further to the research
conducted prior to flotation and the proposed alliance with JL French (UK) Ltd,
led to a decision to manufacture the RingProp in aluminium rather than in the
originally proposed composite material. This important change has led to a
short delay with first commercial sales now anticipated in summer 2004.
However the move to aluminium is expected to accelerate acceptance in the market
place worldwide and lead to a faster build-up of sales volumes. The alliance
with JL French (UK) Ltd secures the source and capacity for high quality product
required to service the company's target markets with the added advantage that
JL French (UK) Ltd will become a shareholder through the agreed financing of the
tooling, thus demonstrating their confidence in the product.

There have been no revenues in the period ended 30 September 2003.

Cavitation testing has been undertaken at Qinetiq's Haslar site, which is the
centre of hydrodynamic research for the Ministry of Defence.

A company research centre has been set up in Melbourne, Australia, where the
test programme has been running since July using instrumentation specially
developed to record the performance of the RingProp in action. Performance is
being measured on a selection of boats and engine sizes, which reflect the
target market of the company, namely engines from 25hp to 250hp.

The test results are being used to ensure high performance across the RingProp
range and full scale manufacture of a range viable for launch is on schedule for
the summer of 2004.

Industry litigation

Current litigation within the US has the potential to precipitate the need for
improved safety, as indicated by the following two cases:

Landmark US Supreme Court ruling

As reported at the time of the interim results, the Supreme Court of the
United States in December 2002, handed down an important judgement
concerning a public liability action against a conventional propeller
manufacturer (Sprietsma vs. Mercury Marine.). This ruling could result in a
significant number of lawsuits being brought by a backlog of injured
parties against outboard engine manufacturers.

Yamaha settles out of court in US

In a more recent case, Yamaha and other defendants settled out of court on
3 September 2003 for $6 million (original claim $63 million) to a claimant
totally paralysed when struck on the arm, head and neck by a propeller.

The directors believe that these developments, and the possible further
litigation derived from them, may contribute to the establishment of the
RingProp propeller as the viable alternative to conventional open-bladed
propellers, offering a safer alternative to the dangerous cutting tips of a
conventional propeller.

Financial

The accounts for the period to 30 September 2003 show a loss of 906,852. The
cash balance was 1,868,232 after flotation costs of 409,680.

I am interested what they do the product is good...

Have a nice day with plenty

Ciao

Well Bonds up, Bema s up Centurion is just about up and the others are stagnant.

I think a lot of investors are waiting to see if the momentum in the US can be maintained. Theres nothing worse in my mind than markets moving sideways.

cheers gf.

what about ACTIF (ACT) tippped in share mag today looks interesting

what do you think of HME now looking like 170p soon

Hi gordon, yup Ive noticed how its been going up, wish I had got in when it was just over a Quid. Id be wary though, Evils still got his sell note on it and if more of his lemmings jump aboard well!!!!!!!!!. Any idea when they next give a trading update? as a lot of retailers have been reporting bad trading october and early november. Your tempting me to go in. I will have a think about this over lunch.

Actif, ive read something in a tip sheet about this recently, will have a look in my watch pile, a cart load of pages taken from tip sheets and mags.

cheers GF.

ciao, im already in Ring Prop. Michael Walters gave me the nod.

cheers gf.

Oh forgot I D DATAS up aswell and Ive found the reason for its lack of northward mobility, in fact you could say its a victim of its own success.
Institutions exercising right to cash in loan notes when shares at 5.5p or over which ever is the greater, issued at 3.5p with 7% interest per annum.
This site ( and other sites jumped aboard) pushed the shares as we thought it was time for next leg up to around was it 11p or more and then instituitions said in effect, sod the interest we will take a 100% plus capital rise by converting notes to shares and then selling.

Cant blame them when they have to meet targets after a 3 year Bear market. Just over 4 million issued.

At some time its going to stop and they will settle for there 7% interest per annum.

This is a great way for the company to raise funds and its happening more all the time now and retail investors in some case can take on the loan notes. The company have a debenture on tangible assets of the company and the loan notes are secured on this.

The only problem is if the share goes like the clappers and gets away like this one.

One good thing is that the company dont have to service the interest on the loan notes sold, so they are happy , institutions are happy and we are as miserable as sin.

cheers GF.

An excelent week allround even IDD is starting to look positive again, only exception being HCEG, but there management is so good that I dont have any problems with them short term.

cheers GF.

Hi GF yes I agree I also had a very profitable week, specially over here, I took big gamble with covered warrants (do you trade CW?) it pay off...my lost turn into profit.......

Lets hope monday will be a good day for TMG.....CASH... CUC...

Ciao

PS I sent you a private messages... but I dont know how to get into myne to see if you answer me...

Cheers Ciao, it hasnt arrived yet. CWs no but I think EC does. I just try and stick to plain old shares, things dont get complicated then.

cheers GF.

BTG

One to put on the watch list, from monday. Has it been oversold given the following research???????.

BTG update November 16, 2003

Elric Lloyd-Langton



BTG an RNS feature on October 10, plunged to 154p from 420 a loss 59% on Friday after the FDA suspended clinical trials of its Varisolve drug.BTG said the US Food and Drug Administration (FDA) had “placed on clinical hold” a Phase II safety study of Varisolve. The news obviously came as a shock to the city, more so given that it was only two weeks ago BTG held an analysts’ briefing on Varisolve’s prospects, at which, according to one analyst present, the company “banged on and on about what a wonderful Varisolve is a non-surgical solution that injects foam into troublesome veins. The none surgical procedure ment that the world’s 150 million sufferers could have their veins treated during a lunch hour, but it also raises medical risks such as deep-vein thrombosis or air emboli.

Analysts viewed Varisolve as the company’s potential blockbuster treatment for varicose veins. Some analyists estimate Varisolve to be worth between $250 million (148 million) and $1 billion.
BTG said the company did not yet know why the FDA had halted trials of the drug, which has already passed pivotal Phase III trials in Europe with flying colours. However, she said the regulator was expected to explain its decision to Provensis, the BTG subsidiary that is developing Varisolve, within the next ten days.

Analysts said the FDA’s decision to suspend the trials was likely to delay a US launch of the drug by at least six months. Although most remained confident that the FDA’s decision related to a minor or procedural issue, some analysts pointed out that there were legitimate safety concerns with the treatment. With no explanation offered for the suspension of the trials it is difficult for investors to gauge the seriousness of the events, clearly some investor ran for the door when news broke. Given that Varisolve passed Phase III trials in Europe with flying colours it appears that investors fears are over done. It is often the case when news events such as this catch investors off guard. There is no doubt that some investors will see this news a buying opportunity for the long term, but the FDA do seem to be holding investors sentiment in their hands.


Edward Kalfayan October 10, 2003

From the BTG trading statement this morning

There are no great surprises ahead of the Interims on Dec 1. There will be a significant increase in revenues as expected, with lower operating costs reduced losses, and good progress across the portfolio.

Preliminary results from a pivotal European Phase III trial for the novel varicose vein technology VARISOLVE(R)were presented at a scientific congress in San Diego on 30 August. VARISOLVE(R) achieved an 83.4% response rate first regulatory submission in Europe as planned in 2004, with the first European launch targeted in 2005.

A Phase II trial is progressing in the US, and data from the second of three 20-patient cohorts is expected to be submitted to the US FDA by end December. Construction of a shell facility and small scale manufacturing production line continues in the UK. Discussions with potential partners have commenced


The market for providing technology commercialisation services to sources of technology and intellectual property has remained strong and 13 new technology commercialisation agreements were signed with academic and corporate sources.

Offering more developed technologies has proven to be attractive to potential licensees or venture partners, and 17 new development projects were authorised to develop technologies further prior to commercialisation.

Two compounds with the potential to treat anxiety and depression were licensed to Abiogen Pharma S.p.A. BTG will investigate BGC 9331 in a Phase I/II trial for its use as a first-line treatment for gastric cancer. BTG and Taiwan's Industrial Technology Research Institute (ITRI) will jointly develop, and BTG will commercialise, a polymer technology for information displays for use in the next generation of laptop computers, mobile phones, PDAs and television sets.

BTG seeks to leverage its core IP, technology and commercial expertise by investing in early stage technology companies with high growth potential. An investment in Cambridge-based Xention Discovery Ltd, will develop drug screening programmes in the cardiovascular and neurology areas. BTG will also be a co-sponsor of a new early stage life sciences fund based in Boston, MA.ENDS.

Has it been oversold, that is the question and its a big gamble. I will be watching very carefully early this coming week.

cheers GF.

Do you understand the dilution on HCEG Goldfinger?

How's JCR going with the interest rate rise momentum that it has to serve on it's massive debt?

Just a word to thread onlookers. The previous poster is a well known trouble maker/idiot whatever. Best to just ignore that type.

cheers gf.

BTG

One to put on the watch list, from monday. Has it been oversold given the following research???????.

BTG update November 16, 2003

Elric Lloyd-Langton



BTG an RNS feature on October 10, plunged to 154p from 420 a loss 59% on Friday after the FDA suspended clinical trials of its Varisolve drug.BTG said the US Food and Drug Administration (FDA) had “placed on clinical hold” a Phase II safety study of Varisolve. The news obviously came as a shock to the city, more so given that it was only two weeks ago BTG held an analysts’ briefing on Varisolve’s prospects, at which, according to one analyst present, the company “banged on and on about what a wonderful Varisolve is a non-surgical solution that injects foam into troublesome veins. The none surgical procedure ment that the world’s 150 million sufferers could have their veins treated during a lunch hour, but it also raises medical risks such as deep-vein thrombosis or air emboli.

Analysts viewed Varisolve as the company’s potential blockbuster treatment for varicose veins. Some analyists estimate Varisolve to be worth between $250 million (148 million) and $1 billion.
BTG said the company did not yet know why the FDA had halted trials of the drug, which has already passed pivotal Phase III trials in Europe with flying colours. However, she said the regulator was expected to explain its decision to Provensis, the BTG subsidiary that is developing Varisolve, within the next ten days.

Analysts said the FDA’s decision to suspend the trials was likely to delay a US launch of the drug by at least six months. Although most remained confident that the FDA’s decision related to a minor or procedural issue, some analysts pointed out that there were legitimate safety concerns with the treatment. With no explanation offered for the suspension of the trials it is difficult for investors to gauge the seriousness of the events, clearly some investor ran for the door when news broke. Given that Varisolve passed Phase III trials in Europe with flying colours it appears that investors fears are over done. It is often the case when news events such as this catch investors off guard. There is no doubt that some investors will see this news a buying opportunity for the long term, but the FDA do seem to be holding investors sentiment in their hands.


Edward Kalfayan October 10, 2003

From the BTG trading statement this morning

There are no great surprises ahead of the Interims on Dec 1. There will be a significant increase in revenues as expected, with lower operating costs reduced losses, and good progress across the portfolio.

Preliminary results from a pivotal European Phase III trial for the novel varicose vein technology VARISOLVE(R)were presented at a scientific congress in San Diego on 30 August. VARISOLVE(R) achieved an 83.4% response rate first regulatory submission in Europe as planned in 2004, with the first European launch targeted in 2005.

A Phase II trial is progressing in the US, and data from the second of three 20-patient cohorts is expected to be submitted to the US FDA by end December. Construction of a shell facility and small scale manufacturing production line continues in the UK. Discussions with potential partners have commenced


The market for providing technology commercialisation services to sources of technology and intellectual property has remained strong and 13 new technology commercialisation agreements were signed with academic and corporate sources.

Offering more developed technologies has proven to be attractive to potential licensees or venture partners, and 17 new development projects were authorised to develop technologies further prior to commercialisation.

Two compounds with the potential to treat anxiety and depression were licensed to Abiogen Pharma S.p.A. BTG will investigate BGC 9331 in a Phase I/II trial for its use as a first-line treatment for gastric cancer. BTG and Taiwan's Industrial Technology Research Institute (ITRI) will jointly develop, and BTG will commercialise, a polymer technology for information displays for use in the next generation of laptop computers, mobile phones, PDAs and television sets.

BTG seeks to leverage its core IP, technology and commercial expertise by investing in early stage technology companies with high growth potential. An investment in Cambridge-based Xention Discovery Ltd, will develop drug screening programmes in the cardiovascular and neurology areas. BTG will also be a co-sponsor of a new early stage life sciences fund based in Boston, MA.ENDS.

Has it been oversold, that is the question and its a big gamble. I will be watching very carefully early this coming week.

cheers GF.

You avoided the questions goldfinger ....can't you answer them?

Is this thread for positive comments only?